What is Vergent Bioscience?
Vergent Bioscience is a clinical-stage biotechnology firm dedicated to revolutionizing cancer surgery. Its lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to help surgeons identify and remove solid tumors with greater precision during real-time procedures. This technology is particularly aimed at improving outcomes in minimally invasive and robotic-assisted surgeries, addressing a critical need for enhanced visualization to ensure complete tumor resection and improve patient care.
How much funding has Vergent Bioscience raised?
Vergent Bioscience has raised a total of $48.9M across 3 funding rounds:
Series A
$8.7M
Series B
$21.5M
Private Equity
$18.7M
Series A (2018): $8.7M, investors not publicly disclosed
Series B (2022): $21.5M led by Colle Capital, Rex Health Ventures, Orlando Health Ventures, Intuitive Surgical, Spring Mountain Capital, and Windham Venture Partners
Private Equity (2025): $18.7M, investors not publicly disclosed
Key Investors in Vergent Bioscience
Colle Capital
Colle Capital Partners is a global early-stage technology venture fund that focuses on investing in innovative entrepreneurs and their bold ideas. The fund emphasizes the importance of data for measuring and managing investments while encouraging agility in a competitive environment. They support a diverse portfolio of companies across various sectors, including artificial intelligence, healthcare, and transportation.
Rex Health Ventures
Rex Health Ventures (RHV) is an innovative platform established by UNC REX Healthcare to support and invest in healthcare technologies and companies. As an early-stage investment fund, it aims to enhance patient care by providing strategic investments to emerging healthcare entrepreneurs across North Carolina and the U.S.
Intuitive Surgical
Intuitive Surgical, Inc commonly known simply as Intuitive is a global medical technology and healthcare innovation company focused on advancing minimally invasive care. The organization designs, manufactures, and markets robotic surgical systems and related instruments that enable surgeons to perform complex procedures with enhanced precision and control.
What's next for Vergent Bioscience?
With the recent major strategic investment, Vergent Bioscience is poised to accelerate the development and commercialization of its VGT-309 technology. The company's focus on improving surgical outcomes for solid tumor patients, especially within the growing field of robotic-assisted surgery, positions it for significant growth. Future endeavors will likely involve further clinical trials, regulatory submissions, and strategic partnerships to broaden the adoption of its imaging agent, ultimately aiming to transform the landscape of cancer surgery and enhance patient recovery.
See full Vergent Bioscience company page
